...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Phase 3 BETonMACE Trial is Now Completed. Cognition and CKD Sub-Study Results to be Announced Soon.

Free
Message: Resverlogix to Present at the Clinical Trials on Alzheimer's Disease Congress 2019

The choice of the word « improves » in the title is interesting. Does it mean cognitive function was better at the end of the trial than at the start, or only that the rate of decline was reduced (so that at the end of the trial CF was better in the ABL group than in the placebo group, but still lower than at baseline).

Either result would be very good, of course, but the former would be a dream. Here’s hoping!

 

Share
New Message
Please login to post a reply